Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Smolen

Showing results (1141-1150 of 1,467) with videos related to

Pageof 147
Sort By:
Annals of the Rheumatic Diseases|June 29, 2011
Changes in patient characteristics in anti-tumour necrosis factor clinical trials for rheumatoid arthritis: results of an analysis of the literature over the past 16 yearsMahboob U Rahman, Jacqui Buchanan, Mittie K Doyle, et al.
Annals of the Rheumatic Diseases|February 25, 2022
Persistence and effectiveness of the IL-12/23 pathway inhibitor ustekinumab or tumour necrosis factor inhibitor treatment in patients with psoriatic arthritis: 1-year results from the real-world PsABio StudyLaure Gossec, Stefan Siebert, Paul Bergmans, et al.
Archives of General Psychiatry|September 7, 2005
A genome-wide search for quantitative trait Loci that influence antisocial drug dependence in adolescenceMichael C Stallings, Robin P Corley, Briana Dennehey, et al.
Annals of the Rheumatic Diseases|January 28, 2006
The Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT): results of radiographic analyses after 1 yearA Kavanaugh, C E Antoni, D Gladman, et al.
The Journal of Rheumatology|September 17, 2018
Safety Profile of Baricitinib in Patients with Active Rheumatoid Arthritis with over 2 Years Median Time in TreatmentJosef S Smolen, Mark C Genovese, Tsutomu Takeuchi, et al.
Annals of the Rheumatic Diseases|February 9, 2020
Safety of synthetic and biological DMARDs: a systematic literature review informing the 2019 update of the EULAR recommendations for the management of rheumatoid arthritisAlexandre Sepriano, Andreas Kerschbaumer, Josef S Smolen, et al.
Annals of the Rheumatic Diseases|November 19, 2008
Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trialJ Smolen, R B Landewé, P Mease, et al.
Plos One|April 20, 2016
A Combination of CD28 (rs1980422) and IRF5 (rs10488631) Polymorphisms Is Associated with Seropositivity in Rheumatoid Arthritis: A Case Control StudyLucia Vernerova, Frantisek Spoutil, Miroslav Vlcek, et al.
ACS Infectious Diseases|June 6, 2020
1,2,3-Triazolylmethaneboronate: A Structure Activity Relationship Study of a Class of β-Lactamase Inhibitors against <i>Acinetobacter baumannii</i> CephalosporinaseEmilia Caselli, Francesco Fini, Maria Luisa Introvigne, et al.
Rheumatology (Oxford, England)|May 28, 2025
Immunoadsorption as a novel therapy for refractory idiopathic inflammatory myopathies: a retrospective observational studyKastriot Kastrati, Thomas Karonitsch, Hanien Rajab, et al.
Pageof 147

Showing results (1141-1150 of 1,467) with videos related to

Sort By:
Pageof 147
Annals of the Rheumatic Diseases|June 29, 2011
Changes in patient characteristics in anti-tumour necrosis factor clinical trials for rheumatoid arthritis: results of an analysis of the literature over the past 16 yearsMahboob U Rahman, Jacqui Buchanan, Mittie K Doyle, et al.
Annals of the Rheumatic Diseases|February 25, 2022
Persistence and effectiveness of the IL-12/23 pathway inhibitor ustekinumab or tumour necrosis factor inhibitor treatment in patients with psoriatic arthritis: 1-year results from the real-world PsABio StudyLaure Gossec, Stefan Siebert, Paul Bergmans, et al.
Archives of General Psychiatry|September 7, 2005
A genome-wide search for quantitative trait Loci that influence antisocial drug dependence in adolescenceMichael C Stallings, Robin P Corley, Briana Dennehey, et al.
Annals of the Rheumatic Diseases|January 28, 2006
The Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT): results of radiographic analyses after 1 yearA Kavanaugh, C E Antoni, D Gladman, et al.
The Journal of Rheumatology|September 17, 2018
Safety Profile of Baricitinib in Patients with Active Rheumatoid Arthritis with over 2 Years Median Time in TreatmentJosef S Smolen, Mark C Genovese, Tsutomu Takeuchi, et al.
Annals of the Rheumatic Diseases|February 9, 2020
Safety of synthetic and biological DMARDs: a systematic literature review informing the 2019 update of the EULAR recommendations for the management of rheumatoid arthritisAlexandre Sepriano, Andreas Kerschbaumer, Josef S Smolen, et al.
Annals of the Rheumatic Diseases|November 19, 2008
Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trialJ Smolen, R B Landewé, P Mease, et al.
Plos One|April 20, 2016
A Combination of CD28 (rs1980422) and IRF5 (rs10488631) Polymorphisms Is Associated with Seropositivity in Rheumatoid Arthritis: A Case Control StudyLucia Vernerova, Frantisek Spoutil, Miroslav Vlcek, et al.
ACS Infectious Diseases|June 6, 2020
1,2,3-Triazolylmethaneboronate: A Structure Activity Relationship Study of a Class of β-Lactamase Inhibitors against <i>Acinetobacter baumannii</i> CephalosporinaseEmilia Caselli, Francesco Fini, Maria Luisa Introvigne, et al.
Rheumatology (Oxford, England)|May 28, 2025
Immunoadsorption as a novel therapy for refractory idiopathic inflammatory myopathies: a retrospective observational studyKastriot Kastrati, Thomas Karonitsch, Hanien Rajab, et al.
Pageof 147